BMS-986403 + fludarabine + cyclophosphamide

BMS-986403 + fludarabine + cyclophosphamide is an **investigational combination therapy** comprising BMS-986403 (a novel agent under development by Bristol Myers Squibb), **fludarabine**, and **cyclophosphamide**. This regimen is being evaluated primarily for the treatment of **relapsed and/or refractory chronic lymphocytic leukemia (CLL)** and **small lymphocytic lymphoma (SLL)** in early-phase (Phase 1) clinical trials. - **BMS-986403**: The specific mechanism of action for BMS-986403 is not publicly disclosed, but it is under investigation as a novel anti-cancer agent for lymphoid malignancies. - **Fludarabine**: A purine analog that interferes with DNA synthesis, leading to inhibition of cancer cell proliferation. - **Cyclophosphamide**: An alkylating agent that crosslinks DNA, resulting in cell death. The typical rationale for combining these agents is to provide immunosuppressive lymphodepletion (via fludarabine and cyclophosphamide) while leveraging the novel anti-cancer properties of BMS-986403.